chartexchange

Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers

GlobeNewswire Inc. | Sep 28, 2026 8:30 AM EDT

Translational research demonstrates that SIL204 utilizes native serum lipids to facilitate intracellular delivery and robust KRAS oncogene knockdown

Read original article